Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 533-545

  Kim, Shiyun ^a   Solari, Hugo ^b   Weiden, Peter J ^b   Bishop, Jeffrey R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Antipsychotic; Long acting injection; Paliperidone; Schizophrenia

Indexed keywords

CLOZAPINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; FLUPHENAZINE ENANTHATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LONG ACTING DRUG; OLANZAPINE; PALIPERIDONE; PLACEBO; RISPERIDONE;

ACUTE DISEASE; AKATHISIA; AMENORRHEA; BINDING AFFINITY; BODY MASS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; DEALKYLATION; DEHYDROGENATION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; EXTRAPYRAMIDAL SYNDROME; GALACTORRHEA; HEADACHE; HUMAN; HYDROXYLATION; IN VITRO STUDY; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; PERSONAL SOCIAL PERFORMANCE SCALE; PHARMACODYNAMICS; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; RHINOPHARYNGITIS; RISK REDUCTION; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; TREMOR; WEIGHT GAIN;

EID: 84882742386     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S20657     Document Type: Review

References (49)

1. Weiden PJ, Solari H, Kim S, Bishop JR. Long-acting injectable antipsychotics and the management of nonadherence. Psychiatr Ann. 2011;41(5):271-278.
2. Junghanns J, Muller R. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3(3):295-309.
3. Once-monthly Invega® Sustenna™ (paliperidone palmitate) extendedrelease injectable suspension [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2011.
4. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet. 2009;48(9):585-600.
5. Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008;36(4):769-779.
6. Invega® paliperidone extended-release tablets [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2006.
7. Hough D, Lindenmayer JP, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(6):1022-1031.
8. Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol. 2010;25(5):247-256.
9. Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr. 2004; 9(10 Suppl 11):6-14.
10. Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010;13(5):635-647.
11. Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010;35(10):2072-2082.
12. Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of three doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30(3):235-244.
13. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-torelapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2-3):107-117.
14. Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol. 2011;25(5):685-697.
15. Fleischhacker WW, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol. July 22, 2011. [Epub ahead of print.]
16. Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injection in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):218-226.
17. Li H, Rui Q, Ning X, Xu H, Gu N. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1002-1008.
18. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519-526.
19. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124(1-2):57-73.
20. Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin. 2010;26(2):377-387.
21. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007;115(4):260-267.
22. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry. 2009;70(10):1397-1406.
23. Patel MX, de Zoysa N, Bernadt M, Bindman J, David AS. Are depot antipsychotics more coercive than tablets? The patient's perspective. J Psychopharmacol. 2010;24(10):1483-1489.
24. Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl. 2009;52: S29-S36.
25. Weiden PJ, Rapkin B, Zygmunt A, Mott T, Goldman D, Frances A. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv. 1995; 46(10):1049-1054.
26. Love RC. Strategies for increasing treatment compliance: the role of long-acting antipsychotics. Am J Health Syst Pharm. 2002;59 (22 Suppl 8):S10-S15.
27. Heinrichs DW, Cohen BP, Carpenter WT Jr. Early insight and the management of schizophrenic decompensation. J Nerv Ment Dis. 1985;173(3):133-138.
28. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886-891.
29. Alia-Klein N, O'Rourke TM, Goldstein RZ, Malaspina D. Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample. Aggress Behav. 2007;33(1):86-96.
30. Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003;12(5):423-424.
31. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70 Suppl 4:1-46.
32. Weiden PJ. Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry. 2007; 68 Suppl 14:14-19.
33. Larsen EB, Gerlach J. Subjective experience of treatment, sideeffects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand. 1996;93(5):381-388.
34. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment. European Neuropshychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol. 1998;8(1):55-66.
35. Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand. 1997;95(6):464-468.
36. Wistedt B. How does the psychiatric patient feel about depot treatment, compulsion or help? Nord J Psychiatry. 1995;49(Suppl 35): 41-46.
37. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry. 1992;53(12):426-433.
38. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1):111-117.
39. Macfadden W, Ma YW, Haskins JT, Bossie CA, Alphs L. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry (Edgmont). 2010;7(11):23-31.
40. Rosenheck RA, Krystal JH, Lew R, et al. Risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9): 842-851.
41. Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010;35(12):2367-2377.
42. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry. 2003;64 Suppl 16:14-17.
43. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after f irst hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603-609.
44. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13(1):27-35.
45. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68(1):29-39.
46. Zyprexa Relprevv® (olanzapine) for extended release injectable suspension [package insert]. Indianapolis, IN: Eli Lilly and Company; 2010.
47. Risperdal Consta® (risperdone) long-acting injection [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2011.
48. Haloperidol decanoate injection [package insert]. Irvine, CA: Teva Parenteral Medicines; 2009.
49. Fluphenazine decanoate injection [package insert]. Bedford, OH: Bedford Laboratories; 2010.